Diane Tutko Francisco, Ph.D., Joins Inotiv to Lead Client Experience Team
May 05 2020 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“Inotiv”, the
“Company”, “We” or “Our”), doing business as Inotiv, a
leading provider of nonclinical and analytical contract research
services, is pleased to announce the addition of Diane Tutko
Francisco, Ph.D., as Sr. Director, Client Experience, effective
April 30, 2020.
Dr. Francisco is an accomplished leader in our
industry, with a history of success in managing teams and
initiatives focused on improving client experiences. Her background
includes skills in program and project management, business process
transformation, and organizational effectiveness. She will lead all
aspects of Inotiv’s Client Experience team, including legacy client
services functions, quote production, and commercial
operations.
Creating Excellent Client Experiences is an
Inotiv core value. The Company’s investments in elevating its
client experiences include recent key hires to support new business
functions in order to drive the integration of the Company’s
services and sites. The Company recently created a business process
excellence function, which is led by Tammy Williams, as well as a
program management function, which is led by Peggy Wyman.
Joe Flynn, the Company’s Chief Commercial
Officer, commented, “Developing a Client Experience team and
driving client centric operations is an important step in
leveraging our platform. We sought a leader with experience in
shaping a culture of excellence, strength in process improvement,
and a passion for delighting clients. We believe we have found that
leader and more in Dr. Francisco,” Mr. Flynn concluded.
“Being part of Inotiv’s client centric growth
strategy is an honor. I look forward to partnering with our
commercial and operational leaders to build a superior end-to-end
customer experience for our clients,” said Dr. Francisco.
Prior to joining Inotiv, Dr. Francisco held
leadership positions with PPD, Covance Laboratories, Inc., and most
recently, with ICON plc, as Director, Clinical Project Management
Office. She earned her BA in Chemistry and Mathematics from
Wartburg College in Waverly, Iowa, and her Ph.D. in Analytical
Chemistry from Purdue University in West Lafayette, Indiana. Dr.
Francisco is a certified Lean Six Sigma Master Black Belt and DDI
Trainer.
About the Company
Bioanalytical Systems, Inc., operating as
Inotiv, is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. The Company’s products focus on
increasing efficiency, improving data, and reducing the cost of
taking new drugs to market. Visit inotivco.com for more
information about the Company.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, the impact of COVID-19 on the
economy, demand for our products and services and our operations,
and various market and operating risks, including those detailed in
the Company's filings with the U.S. Securities and Exchange
Commission.
FOR MORE INFORMATION:Company
Contact:Beth A. TaylorChief Financial OfficerPhone:
765.497.8381btaylor@inotivco.com
A photo accompanying this announcement is
available
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/72c5f0ae-b4d2-48ad-9c0c-f3fa472e8bc6
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024